美股周一交易时段，生物技术公司Celcuity Inc（CELC）股价盘中大涨47.15%，引发市场广泛关注。
此次股价暴涨主要源于公司在2025年ESMO（欧洲肿瘤内科学会）年会上发布的积极研究数据。Celcuity展示了其Gedatolisib联合Darolutamide治疗转移性去势抵抗性前列腺癌（mCRPC）患者的I期研究最新数据，结果显示出显著的治疗效果。
据悉，这项研究的初步数据显示，Gedatolisib联合Darolutamide在治疗mCRPC患者方面具有良好的安全性和有效性。这一结果为Celcuity在前列腺癌治疗领域的发展注入了强劲动力，也增强了投资者对公司未来发展前景的信心。市场分析人士认为，如果后续临床试验继续取得积极结果，Celcuity有望在竞争激烈的肿瘤治疗市场中占据重要地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.